Literature DB >> 29927703

Outcomes Using Cryoablation for Postoperative Pain Control in Children Following Minimally Invasive Pectus Excavatum Repair.

Joseph Sujka1, Leo Andrew Benedict1, Jason D Fraser1, Pablo Aguayo1, Daniel L Millspaugh2, Shawn D St Peter1.   

Abstract

PURPOSE: Pain is the main factor that determines the postoperative course for patients undergoing pectus bar placement. Cryoablation of the intercostal nerves has been suggested to mitigate this pain. We instituted a protocol for using intercostal cryoablation and report our early results compared to our immediately previous cohort.
MATERIALS AND METHODS: A retrospective study was conducted on patients undergoing minimally invasive repair for pectus excavatum between January 1, 2017, and August 21, 2017. Demographic data, anthropometrics, operative times, type and duration of patient analgesia, and postoperative length of stay were collected. Descriptive statistics were performed with all means reported ± standard deviations. Comparisons between groups were analyzed on STATA using T-tests with a P value <.05 determined as significant.
RESULTS: Twenty-eight patients were treated for pectus excavatum during the study period with 9 (32%) undergoing cryoablation. Mean number of rib spaces ablated was 5 ± 0.53 with no reported intraoperative complications. Mean operative time was 30 minutes longer in the cryoablation group (P = .00). Days to only oral pain medication was shorter in the cryoablation group, (1.22 ± 0.66 day versus 2.63 ± 0.68 day, P = .00). Length of stay, in days, was shorter in the cryoablation group (1.4 ± 0.72 days versus 4.0 ± 1.0 days, P = .00). There were no reported complications from cryoablation or bar placement during the study period. Days to discontinuation of oral narcotics were less in the cryoablation group (8.2 ± 7.0 versus 18.2 ± 10.4, P = .00).
CONCLUSION: Cryoablation after pectus bar placement dramatically decreases narcotic usage and postoperative length of stay.

Entities:  

Keywords:  cryoablation; epidural; minimally invasive; patient-controlled anesthesia; pectus excavatum

Mesh:

Substances:

Year:  2018        PMID: 29927703     DOI: 10.1089/lap.2018.0111

Source DB:  PubMed          Journal:  J Laparoendosc Adv Surg Tech A        ISSN: 1092-6429            Impact factor:   1.878


  6 in total

Review 1.  Anaesthesia for the surgical correction of chest wall deformities.

Authors:  T Ghafoor; M Edsell; I Hunt
Journal:  BJA Educ       Date:  2020-07-01

2.  Intraoperative intercostal nerve cryoablation During the Nuss procedure reduces length of stay and opioid requirement: A randomized clinical trial.

Authors:  Claire E Graves; Jarrett Moyer; Michael J Zobel; Roberto Mora; Derek Smith; Maura O'Day; Benjamin E Padilla
Journal:  J Pediatr Surg       Date:  2019-03-17       Impact factor: 2.545

3.  A New Device for Thoracoscopic Cryoanalgesia in Pectus Excavatum Repair: Preliminary Single Center Experience.

Authors:  Michele Torre; Leila Mameli; Rachele Bonfiglio; Vittorio Guerriero; Lucia Derosas; Loredana Palomba; Nicola Disma
Journal:  Front Pediatr       Date:  2021-01-18       Impact factor: 3.418

4.  Limited cryoablation reduces hospital stay and opioid consumption compared to thoracic epidural analgesia after minimally invasive repair of pectus excavatum.

Authors:  Seung Hwan Song; Duk Hwan Moon; Yon Hee Shim; Hyunjoo Jung; Sungsoo Lee
Journal:  Medicine (Baltimore)       Date:  2022-08-05       Impact factor: 1.817

5.  Efficacy of intercostal cryoneurolysis as an analgesic adjunct for chest wall pain after surgery or trauma: systematic review.

Authors:  Peter I Cha; Jung Gi Min; Advait Patil; Jeff Choi; Nishita N Kothary; Joseph D Forrester
Journal:  Trauma Surg Acute Care Open       Date:  2021-05-18

6.  Intercostal nerve cryoablation is associated with lower hospital cost during minimally invasive Nuss procedure for pectus excavatum.

Authors:  Taylor J Aiken; Christopher C Stahl; Deborah Lemaster; Timothy W Casias; Benjamin J Walker; Peter F Nichol; Charles M Leys; Daniel E Abbott; Adam S Brinkman
Journal:  J Pediatr Surg       Date:  2020-10-19       Impact factor: 2.549

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.